Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1601-5215.2011.00559.xDOI Listing

Publication Analysis

Top Keywords

aripiprazole-induced tardive
4
tardive dyskinesia
4
dyskinesia treated
4
treated quetiapine
4
quetiapine case
4
case report
4
aripiprazole-induced
1
dyskinesia
1
treated
1
quetiapine
1

Similar Publications

We report the case of a 23-year-old man who developed orofacial dyskinesia secondary to aripiprazole whilst being treated for psychosis in the hospital. He was known to mental health services and had suffered a relapse of bipolar affective disorder. Upon cessation of aripiprazole and commencement of quetiapine, there was a rapid reversal of his movement disorder.

View Article and Find Full Text PDF

Oculogyric crisis (OGC) represent an unusual type of dystonic movement disorder, usually reported as an adverse event of antipsychotic drugs, with acute or tardive onset, likely due to a functional disruption of dopaminergic neurotransmission. It is seldom reported in children with aripiprazole, an atypical antipsychotic commonly used in youths. In this manuscript, we report on a case series of three pediatric patients and provide a brief narrative review of the literature, in order to increase the awareness of clinicians and to foster future research in this area.

View Article and Find Full Text PDF

In the last years second-generation antipsychotics are increasingly prescribed in the pediatric population for the treatment of several psychiatric disorders. Among the long term adverse effects, extrapyramidal symptoms (EPS) are less reported compared to first-generation antipsychotics. Tardive dyskinesia (TD) is a iatrogenic rare syndrome characterized by persistent slow writhing and sudden involuntary movements mainly involving the oral-buccal-lingual area with masticatory movements.

View Article and Find Full Text PDF

Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole.

Neurologist

January 2017

*Unité des Troubles du Mouvement André Barbeau †Division of Neurology, Centre Hospitalier de l'Université de Montréal Departments of ‡Neuroscience §Pharmacology, Université de Montréal ∥Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

Objectives: Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. Because of its partial agonist activity, it was believed that aripiprazole would be less susceptible than typical antipsychotics to induce extrapyramidal side effects. However, a few case-reports and case-series detailing aripiprazole-induced movement disorders have been published, suggesting that aripiprazole-induced movement disorders may arise.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!